Status:
RECRUITING
Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC
Lead Sponsor:
Hunan Province Tumor Hospital
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in HER 2 insertion or amplification.
Detailed Description
Main enrolled criteria: Her2 insertion advanced NSCLC Her 2 amplification advanced NSCLC Failed with standard chemotherapy No history of PD-1/ PD-L1 antibody using
Eligibility Criteria
Inclusion
- ≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
- HER 2 Insertion or Amplification
- First Diagnosis and Treatment
- Treatment Plan is Chemotherapy or Chemotherapy plus PD-1 antibody
Exclusion
- Patients received antitumor treatment before
- Patients with contraindication of chemotherapy
- Pregnant or breast feeding women
Key Trial Info
Start Date :
March 24 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 24 2025
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT04324125
Start Date
March 24 2020
End Date
March 24 2025
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yongchang Zhang
Changsha, Hunan, China, 410013